Related Experiment Video
Updated: Nov 12, 2025
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.5K
Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence
Oleh Lushchak1, Veronika Piskovatska2, Olha Strilbytska3
1Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, Ivano-Frankivsk, Ukraine. oleh.lushchak@pnu.edu.ua.
Advances in Experimental Medicine and Biology
|March 16, 2021
Summary
Aspirin, a common painkiller, shows potential as a geroprotector, slowing aging and extending lifespan. While offering benefits like cardiovascular protection and anti-cancer effects, potential risks such as bleeding must be considered.
Area of Science:
- Gerontology and aging research.
- Pharmacology and drug discovery.
- Biomedical science and disease prevention.
Background:
- Aging is a complex biological process marked by functional decline and increased disease risk.
- Geroprotectors are compounds that slow aging and extend lifespan.
- Aspirin (acetylsalicylic acid), a non-steroidal anti-inflammatory drug (NSAID), is being investigated for its geroprotective potential.
Purpose of the Study:
- To review the clinical efficacy of aspirin as an anti-aging drug.
- To explore aspirin's potential in preventing age-related diseases.
- To summarize evidence supporting aspirin's health and longevity benefits.
Main Methods:
- Review of experimental and analytical data on aspirin's effects.
- Examination of clinical evidence for cardiovascular disease prevention.
- Assessment of anti-cancer and cognitive function improvement data.
Main Results:
- Aspirin demonstrates life-extending effects in model organisms.
- Evidence suggests aspirin's efficacy in cardiovascular disease prevention.
- Potential anti-cancer and cognitive benefits are supported by data.
- Pro-longevity pathways are influenced by aspirin treatment.
Conclusions:
- Aspirin exhibits promising geroprotective properties, potentially slowing aging and extending lifespan.
- Clinical benefits include cardiovascular protection and possible anti-cancer effects.
- Risk of excessive bleeding is a significant limitation requiring careful consideration.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
80
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
80
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
827
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
827
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
72
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
72
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
316
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
316
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
75
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
75
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
791
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
791